Rubicon Research · risk themes across the available quarters.
Bear-case history
Demand has exceeded internal capacity more than anticipated, forcing greater reliance on outsourced manufacturing which compresses gross margins in the near term. Management described this as a 'good problem' but acknowledged it will be 'gross margin negative in the near term'.
An analyst questioned how the company accounts for FDA approval timing variability, citing recent regulatory uncertainties for Indian companies in Canada and US. Management responded that they factor in conservatism but did not provide specific buffer percentages or contingency plans.
Inventory stands at Rs 685 crore, with 25-30% allocated to recent and upcoming launches. While management cited this as 'fuel for growth' and highlighted 34% ROC, the scale of inventory investment represents a working capital risk if launch timelines slip.
98% of revenues are USD-denominated, exposing the company to currency volatility. The analyst did not ask about hedging strategy, and management did not voluntarily address FX risk mitigation.